The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Noxafil     4-[4-[4-[4-[[(5S)-5-(2,4- difluorophenyl)-5...

Synonyms: SureCN37449, HSDB 7421, LS-186118, LS-186988, LS-187630, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Sch 56592


High impact information on Sch 56592


Chemical compound and disease context of Sch 56592


Biological context of Sch 56592


Anatomical context of Sch 56592


Associations of Sch 56592 with other chemical compounds


Gene context of Sch 56592

  • However, the midazolam AUC((tf)) was higher in the posaconazole than no-treatment group (93.4 n gh/ml versus 51.4 ng h/ml, P<0.01), indicating inhibition of hepatic CYP3A4 [21].
  • Based on insignificant differences in mean probe ratios, posaconazole did not inhibit CYP1A2, 2C8/9, 2D6, or 2E1 [21].
  • Despite both the increases in pump expression and the ERG11 mutations, only one of the patient isolates exhibited a large decrease in posaconazole susceptibility [22].
  • Screening of 10 cDNA-expressed recombinant human UDP-glucuronosyltransferase (UGT) enzymes showed that only UGT1A4 exhibited catalytic activity with respect to the formation of the glucuronide of posaconazole [23].
  • Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study [21].

Analytical, diagnostic and therapeutic context of Sch 56592


  1. Clinical efficacy of new antifungal agents. Kauffman, C.A. Curr. Opin. Microbiol. (2006) [Pubmed]
  2. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Imai, J.K., Singh, G., Clemons, K.V., Stevens, D.A. Antimicrob. Agents Chemother. (2004) [Pubmed]
  3. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., Loebenberg, D. Antimicrob. Agents Chemother. (2004) [Pubmed]
  4. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Connolly, P., Wheat, L.J., Schnizlein-Bick, C., Durkin, M., Kohler, S., Smedema, M., Goldberg, J., Brizendine, E., Loebenberg, D. Antimicrob. Agents Chemother. (2000) [Pubmed]
  5. Posaconazole. Keating, G.M. Drugs (2005) [Pubmed]
  6. Posaconazole Enhances the Activity of Amphotericin B against Aspergillus Hyphae In Vitro. Perkhofer, S., Lugger, H., Dierich, M.P., Lass-Flörl, C. Antimicrob. Agents Chemother. (2007) [Pubmed]
  7. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Sansone-Parsons, A., Krishna, G., Simon, J., Soni, P., Kantesaria, B., Herron, J., Stoltz, R. Antimicrob. Agents Chemother. (2007) [Pubmed]
  8. Posaconazole prophylaxis in experimental systemic zygomycosis. Barchiesi, F., Spreghini, E., Santinelli, A., Fothergill, A.W., Pisa, E., Giannini, D., Rinaldi, M.G., Scalise, G. Antimicrob. Agents Chemother. (2007) [Pubmed]
  9. Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Patera, A.C., Menzel, F., Jackson, C., Brieland, J.K., Halpern, J., Hare, R., Cacciapuoti, A., Loebenberg, D. Antimicrob. Agents Chemother. (2004) [Pubmed]
  10. The Anti-Trypanosoma cruzi Activity of Posaconazole in a Murine Model of Acute Chagas' Disease Is Less Dependent on Gamma Interferon than That of Benznidazole. Ferraz, M.L., Gazzinelli, R.T., Alves, R.O., Urbina, J.A., Romanha, A.J. Antimicrob. Agents Chemother. (2007) [Pubmed]
  11. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. Carrillo-Muñoz, A.J., Quindós, G., Ruesga, M., Alonso, R., del Valle, O., Hernández-Molina, J.M., McNicholas, P., Loebenberg, D., Santos, P. J. Antimicrob. Chemother. (2005) [Pubmed]
  12. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Aperis, G., Mylonakis, E. Expert opinion on investigational drugs. (2006) [Pubmed]
  13. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J., Laughlin, M. Clinical pharmacokinetics. (2005) [Pubmed]
  14. Disposition of posaconazole following single-dose oral administration in healthy subjects. Krieter, P., Flannery, B., Musick, T., Gohdes, M., Martinho, M., Courtney, R. Antimicrob. Agents Chemother. (2004) [Pubmed]
  15. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Gubbins, P.O., Krishna, G., Sansone-Parsons, A., Penzak, S.R., Dong, L., Martinho, M., Anaissie, E.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  16. Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. Paul, S., Marty, F.M., Colson, Y.L. Ann. Thorac. Surg. (2006) [Pubmed]
  17. Posaconazole: clinical pharmacology and potential for management of fungal infections. Groll, A.H., Walsh, T.J. Expert review of anti-infective therapy. (2005) [Pubmed]
  18. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M.J., Monzon, A., Rodriguez-Tudela, J.L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  19. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Al-Abdely, H.M., Najvar, L.K., Bocanegra, R., Graybill, J.R. Antimicrob. Agents Chemother. (2005) [Pubmed]
  20. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, R.N., Doern, G.V., Brandt, M.E., Hajjeh, R.A. Antimicrob. Agents Chemother. (1998) [Pubmed]
  21. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., Laughlin, M. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. (2004) [Pubmed]
  22. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Chau, A.S., Mendrick, C.A., Sabatelli, F.J., Loebenberg, D., McNicholas, P.M. Antimicrob. Agents Chemother. (2004) [Pubmed]
  23. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Ghosal, A., Hapangama, N., Yuan, Y., Achanfuo-Yeboah, J., Iannucci, R., Chowdhury, S., Alton, K., Patrick, J.E., Zbaida, S. Drug Metab. Dispos. (2004) [Pubmed]
  24. Posaconazole as salvage therapy for zygomycosis. Greenberg, R.N., Mullane, K., van Burik, J.A., Raad, I., Abzug, M.J., Anstead, G., Herbrecht, R., Langston, A., Marr, K.A., Schiller, G., Schuster, M., Wingard, J.R., Gonzalez, C.E., Revankar, S.G., Corcoran, G., Kryscio, R.J., Hare, R. Antimicrob. Agents Chemother. (2006) [Pubmed]
  25. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Brugière, O., Dauriat, G., Mal, H., Marrash-Chalha, R., Fournier, M., Groussard, O., Besnard, M., Lesèche, G., Dupont, B. Transplantation (2005) [Pubmed]
  26. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Courtney, R., Pai, S., Laughlin, M., Lim, J., Batra, V. Antimicrob. Agents Chemother. (2003) [Pubmed]
  27. Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers. Sansone-Parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M.A., Saltzman, M.A. Antimicrob. Agents Chemother. (2006) [Pubmed]
WikiGenes - Universities